Looking Ahead: Potential Sequencing Strategies and Focusing On a Patient-Centered Approach to Treatment of HER2-Mutated NSCLC
June 13th 2025
Panelists discuss how sequencing strategies for multiple HER2-targeted therapies will require careful consideration of patient characteristics, disease burden, and prior treatments, with oral tyrosine kinase inhibitors potentially preferred first due to better tolerability and CNS activity, while combination approaches remain investigational pending safety and efficacy data.